Gibney, Geoffrey T. https://orcid.org/0000-0002-5401-8498
Zaemes, Jacob
Shand, Shelly
Shah, Neil J.
Swoboda, David
Gardner, Kellie
Radfar, Arash
Petronic-Rosic, Vesna
Reilly, Michael J.
Al-Refaie, Waddah B.
Rapisuwon, Suthee https://orcid.org/0000-0002-1389-925X
Atkins, Michael B. https://orcid.org/0000-0003-3901-9924
Clinical trials referenced in this document:
Documents that mention this clinical trial
PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma
https://doi.org/10.1136/jitc-2021-002955
Considerations for treatment duration in responders to immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2020-001901
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Documents that mention this clinical trial
PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma
https://doi.org/10.1136/jitc-2021-002955
Considerations for treatment duration in responders to immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2020-001901
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947